A severe case of bevacizumab-induced thrombotic microangiopathy

Bektas M., Samanci N., Cokgezer S., Keskin D., Demirelli F. H.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.25, sa.7, ss.1754-1757, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 7
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1177/1078155218800371
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1754-1757
  • İstanbul Üniversitesi Adresli: Evet

Özet

Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.